UG2 Stock Overview
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AngioDynamics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.05 |
| 52 Week High | US$10.20 |
| 52 Week Low | US$4.76 |
| Beta | 0.68 |
| 1 Month Change | 24.49% |
| 3 Month Change | 14.15% |
| 1 Year Change | -24.38% |
| 3 Year Change | -68.97% |
| 5 Year Change | -67.11% |
| Change since IPO | -44.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| UG2 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -3.2% | -2.1% | -0.8% |
| 1Y | -24.4% | -3.3% | 1.0% |
Return vs Industry: UG2 underperformed the German Medical Equipment industry which returned -3.3% over the past year.
Return vs Market: UG2 underperformed the German Market which returned 1% over the past year.
Price Volatility
| UG2 volatility | |
|---|---|
| UG2 Average Weekly Movement | 6.6% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UG2 has not had significant price volatility in the past 3 months.
Volatility Over Time: UG2's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 815 | Jim Clemmer | www.angiodynamics.com |
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company’s thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure.
AngioDynamics, Inc. Fundamentals Summary
| UG2 fundamental statistics | |
|---|---|
| Market cap | €245.42m |
| Earnings (TTM) | -€181.06m |
| Revenue (TTM) | €304.96m |
0.8x
P/S Ratio-1.4x
P/E RatioIs UG2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UG2 income statement (TTM) | |
|---|---|
| Revenue | US$324.01m |
| Cost of Revenue | US$164.37m |
| Gross Profit | US$159.64m |
| Other Expenses | US$352.01m |
| Earnings | -US$192.37m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.80 |
| Gross Margin | 49.27% |
| Net Profit Margin | -59.37% |
| Debt/Equity Ratio | 0% |
How did UG2 perform over the long term?
See historical performance and comparison